Current limitations across pricing, coverage, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. 

Returning for its 2nd edition, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape.

Industry-led discussions will center on innovative payment models being developed and applied, new stop-loss and reinsurance programs, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes, including the Access Model, Medicaid Drug Rebate Program Final Rule, and proposed increases to inpatient CAR-T reimbursement rates.

Join leading biopharma, government agencies, commercial payers, academics, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies, enhance your payer coverage and improve patient access.